USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$183.36M
Market Cap
-
P/E Ratio
-12356.9
EPS
$817.50
52 Week High
$4.51
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$62K |
| Total Revenue | $520K |
| Cost Of Revenue | $582K |
| Costof Goods And Services Sold | $582K |
| Operating Income | -$14M |
| Selling General And Administrative | $9.5M |
| Research And Development | $3.7M |
| Operating Expenses | $14M |
| Investment Income Net | - |
| Net Interest Income | -$17K |
| Interest Income | - |
| Interest Expense | $17K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $60K |
| Income Before Tax | -$12M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$14M |
| Ebitda | -$14M |
| Net Income | -$12M |
| Field | Value (USD) |
|---|---|
| Total Assets | $3.5M |
| Total Current Assets | $3.4M |
| Cash And Cash Equivalents At Carrying Value | $1.1M |
| Cash And Short Term Investments | $1.1M |
| Inventory | $1M |
| Current Net Receivables | $635K |
| Total Non Current Assets | $125K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $658K |
| Other Non Current Assets | - |
| Total Liabilities | $2.5M |
| Total Current Liabilities | $2.2M |
| Current Accounts Payable | $873K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $24K |
| Total Non Current Liabilities | $320K |
| Capital Lease Obligations | $12K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $12K |
| Other Current Liabilities | $1.2M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $1.1M |
| Treasury Stock | - |
| Retained Earnings | -$172M |
| Common Stock | $4K |
| Common Stock Shares Outstanding | $2.7M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$11M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $60K |
| Capital Expenditures | $5K |
| Change In Receivables | - |
| Change In Inventory | -$607K |
| Profit Loss | - |
| Cashflow From Investment | -$5K |
| Cashflow From Financing | $7M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$12M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$62K |
| Total Revenue | $520K |
| Cost Of Revenue | $582K |
| Costof Goods And Services Sold | $582K |
| Operating Income | -$14M |
| Selling General And Administrative | $9.5M |
| Research And Development | $3.7M |
| Operating Expenses | $14M |
| Investment Income Net | - |
| Net Interest Income | -$17K |
| Interest Income | - |
| Interest Expense | $17K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $60K |
| Income Before Tax | -$12M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$14M |
| Ebitda | -$14M |
| Net Income | -$12M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Helius Medical Technologies, Inc. (HSDT) is a pioneering neurotechnology company focused on developing and commercializing non-invasive therapies designed to alleviate symptoms related to neurological disorders and trauma. The company leverages cutting-edge technologies to meet significant unmet medical needs in the neurorehabilitation market, demonstrating a strong commitment to improving patient outcomes and enhancing quality of life for individuals affected by these conditions. Based in Newtown, Pennsylvania, Helius is well-positioned for growth and impact within the rapidly evolving healthcare sector.